Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study

BACKGROUND: In metastatic breast cancer (MBC) patients, randomised controlled trials evaluated Bevacizumab as first-line treatment showed improvements in tumour response rate and progression-free survival (PFS) when added to chemotherapy. In Morocco, we conducted an observational study to investigat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Boulaamane, Lamiaa, Boutayeb, Saber, Errihani, Hassan
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2012
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3337253/
https://ncbi.nlm.nih.gov/pubmed/22439740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-5-162
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars